Pandemic influenza vaccine H5N1 AstraZeneca 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0054 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/10/2022 
Veterinary Medicinal Products - Other variation 
amended 
on 
SmPC, 
Labelling and 
PL 
IA/0051/G 
This was an application for a group of variations. 
13/07/2022 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
WS/2219/G 
This was an application for a group of variations 
07/07/2022 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0049 
B.II.b.3.z - Change in the manufacturing process of 
29/04/2022 
n/a 
the finished or intermediate product - Other variation 
II/0048/G 
This was an application for a group of variations. 
22/04/2022 
n/a 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
Page 2/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
method at the site is a biol/immunol method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
R/0047 
Renewal of the marketing authorisation. 
27/01/2022 
04/03/2022 
WS/2182/G 
This was an application for a group of variations 
16/12/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 3/17 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202105 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
IA/0046 
B.II.d.2.a - Change in test procedure for the finished 
05/11/2021 
n/a 
product - Minor changes to an approved test 
procedure 
WS/2079/G 
This was an application for a group of variations 
24/06/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.II.c.z - Change in control of excipients in the 
Finished Product - Other variation 
B.II.c.1.z - Change in the specification parameters 
and/or limits of an excipient - Other variation 
IB/0042 
A.5.a - Administrative change - Change in the name 
14/05/2021 
04/03/2022 
SmPC, Annex 
Page 4/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer/importer 
responsible for batch release 
II, Labelling 
and PL 
IA/0043 
A.4 - Administrative change - Change in the name 
07/05/2021 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0040 
Renewal of the marketing authorisation. 
28/01/2021 
10/03/2021 
WS/1943/G 
This was an application for a group of variations 
14/01/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
WS/1942/G 
This was an application for a group of variations 
14/01/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.1.f - Change in the manufacturer of AS or of a 
Page 5/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.I.b.2.z - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
variation 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202005 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
IB/0036 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/10/2020 
10/03/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
WS/1809/G 
This was an application for a group of variations 
09/07/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
Page 6/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
of the AS 
WS/1824 
This was an application for a variation following a 
25/06/2020 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.c.z - Change in control of excipients in the 
Finished Product - Other variation 
IB/0032/G 
This was an application for a group of variations. 
25/03/2020 
10/03/2021 
SmPC, Annex 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
R/0031 
Renewal of the marketing authorisation. 
30/01/2020 
16/03/2020 
WS/1739 
This was an application for a variation following a 
12/12/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.z - Quality change - Active substance - Other 
variation 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
Page 7/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1142 
A.7 - Administrative change - Deletion of 
11/09/2019 
n/a 
manufacturing sites 
IG/1143 
B.II.b.2.c.1 - Change to importer, batch release 
26/08/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
WS/1646 
This was an application for a variation following a 
25/07/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IG/1115/G 
This was an application for a group of variations. 
28/06/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0019 
Renewal of the marketing authorisation. 
28/02/2019 
17/04/2019 
IB/0023/G 
This was an application for a group of variations. 
28/03/2019 
16/03/2020 
Annex II and 
PL 
Page 8/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
WS/1533 
This was an application for a variation following a 
14/02/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
Page 9/17 
 
 
 
 
 
 
 
 
 
 
WS/1552 
This was an application for a variation following a 
14/02/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
II/0020/G 
This was an application for a group of variations. 
14/02/2019 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
Page 10/17 
 
 
 
 
 
 
 
 
 
 
 
 
impact on the quality, safety or efficacy of the 
medicinal product 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 11/17 
 
 
 
 
 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.c.1.b - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition for 
sterile and non-frozen biological/immunological ASs 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 12/17 
 
 
 
 
 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
B.II.d.2.c - Change in test procedure for the finished 
product - Substantial change to or replacement of a 
biol/immunol/immunochemical test method or a 
method using a biol. reagent or replacement of a 
biol. reference preparation not covered by an 
approved protocol 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201805 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
WS/1499 
This was an application for a variation following a 
22/11/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
II/0015 
Update of section 4.6 of the SmPC with regard to 
26/07/2018 
17/04/2019 
SmPC 
There are no data available on the use of Pandemic 
pregnancy information based on cumulative review 
influenza vaccine H5N1 AstraZeneca in pregnant women. 
Page 13/17 
 
 
 
 
 
 
 
 
 
 
 
 
of pregnancy data from clinical trials, published 
literature and MAH pharmacovigilance database. The 
MAH took the opportunity to include editorial 
changes in section 4.8 and 5.1 of the SmPC. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
There is a moderate amount of data from the use of Fluenz 
Tetra in pregnant women, which is considered relevant to 
the Pandemic influenza vaccine. In more than 300 case 
reports in the MAH’s safety database of vaccine 
administration to pregnant women, no unusual patterns of 
pregnancy complications or foetal outcomes were observed. 
IG/0954 
A.7 - Administrative change - Deletion of 
13/07/2018 
n/a 
manufacturing sites 
WS/1395 
This was an application for a variation following a 
28/06/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
R/0011 
Renewal of the marketing authorisation. 
22/02/2018 
04/04/2018 
IG/0907 
B.II.d.1.a - Change in the specification parameters 
26/03/2018 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0012 
B.I.b.2.a - Change in test procedure for AS or 
01/03/2018 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
II/0009/G 
This was an application for a group of variations. 
25/01/2018 
n/a 
Page 14/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
/201705 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
IA/0010/G 
This was an application for a group of variations. 
05/10/2017 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0008/G 
This was an application for a group of variations. 
20/09/2017 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 15/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
T/0005 
Transfer of Marketing Authorisation 
27/05/2017 
23/06/2017 
SmPC, 
Labelling and 
PL 
PSUSA/10501
Periodic Safety Update EU Single assessment - 
09/06/2017 
n/a 
PRAC Recommendation - maintenance 
/201611 
pandemic influenza vaccine (H5N1) (live attenuated, 
nasal) 
IAIN/0006 
A.2.a - Administrative change - Change in the 
24/05/2017 
23/06/2017 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
R/0003 
Renewal of the marketing authorisation. 
23/02/2017 
20/04/2017 
IB/0002/G 
This was an application for a group of variations. 
14/01/2017 
20/04/2017 
SmPC 
B.II.d.1.b - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits for medicinal products subject to 
OCABR 
C.I.z - Changes (Safety/Efficacy) of Human and 
Page 16/17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Medicinal Products - Other variation 
IA/0001/G 
This was an application for a group of variations. 
25/11/2016 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.c.3.z - Change in source of an excipient or 
reagent with TSE risk - Other variation 
Page 17/17 
 
 
 
 
 
 
 
 
 
 
 
